

officer of the Commission to represent the interests of the general public in the proceeding, pursuant to 39 U.S.C. 505 (Public Representative). Section II also establishes comment deadline(s) pertaining to each request.

The public portions of the Postal Service's request(s) can be accessed via the Commission's website (<http://www.prc.gov>). Non-public portions of the Postal Service's request(s), if any, can be accessed through compliance with the requirements of 39 CFR 3011.301.¹

The Commission invites comments on whether the Postal Service's request(s) in the captioned docket(s) are consistent with the policies of title 39. For request(s) that the Postal Service states concern market dominant product(s), applicable statutory and regulatory requirements include 39 U.S.C. 3622, 39 U.S.C. 3642, 39 CFR part 3030, and 39 CFR part 3040, subpart B. For request(s) that the Postal Service states concern competitive product(s), applicable statutory and regulatory requirements include 39 U.S.C. 3632, 39 U.S.C. 3633, 39 U.S.C. 3642, 39 CFR part 3035, and 39 CFR part 3040, subpart B. Comment deadline(s) for each request appear in section II.

II. Docketed Proceeding(s)

1. *Docket No(s)*: MC2023–25 and CP2023–24; *Filing Title*: USPS Request to Add Priority Mail Express, Priority Mail, First-Class Package Service & Parcel Select Contract 73 to Competitive Product List and Notice of Filing Materials Under Seal; *Filing Acceptance Date*: October 21, 2022; *Filing Authority*: 39 U.S.C. 3642, 39 CFR 3040.130 through 3040.135, and 39 CFR 3035.105; *Public Representative*: Jethro Dely; *Comments Due*: October 31, 2022.

This Notice will be published in the **Federal Register**.

Erica A. Barker,
Secretary.

[FR Doc. 2022–23450 Filed 10–27–22; 8:45 am]

BILLING CODE 7710–FW–P

PRIVACY AND CIVIL LIBERTIES OVERSIGHT BOARD

[Notice-PCLOB–2022–02; Docket No. 2022–0009; Sequence No. 2]

Notice of Public Forum; Extension of Comment Period

AGENCY: Privacy and Civil Liberties
Oversight Board (PCLOB).

¹ See Docket No. RM2018–3, Order Adopting Final Rules Relating to Non-Public Information, June 27, 2018, Attachment A at 19–22 (Order No. 4679).

ACTION: Notice; Extension of comment period.

SUMMARY: The PCLOB, or Board, is extending the comment period for the notice announcing a request for comments on the Board's Oversight Project examining Section 702 of the Foreign Intelligence Surveillance Act (FISA) that appeared in the **Federal Register** of September 26, 2022.

DATES: The Board is extending the comment period announced in the notice and request for comments published on September 26, 2022 (87 FR 58393) to Friday, November 4, 2022.

FOR FURTHER INFORMATION CONTACT: Alan Silverleib, Public and Legislative Affairs Officer at 202–997–7719; pao@pclob.gov.

Lois D. Mandell,

*Director, Regulatory Secretariat Division,
Office of Government-Wide Policy, General
Services Administration.*

[FR Doc. 2022–23530 Filed 10–27–22; 8:45 am]

BILLING CODE 6820–B5–P

OFFICE SCIENCE AND TECHNOLOGY POLICY

Request for Information on Data Collection for Emergency Clinical Trials and Interoperability Pilot

AGENCY: Office of Science and
Technology Policy (OSTP).

ACTION: Notice of Request for
Information (RFI) on Data Collection for
Emergency Clinical Trials and
Interoperability Pilot.

SUMMARY: As described in the recent RFI on Clinical Research Infrastructure and Emergency Clinical Trials, the White House Office of Science and Technology Policy (OSTP), in partnership with the National Security Council (NSC), is leading efforts to ensure that coordinated and large-scale clinical trials can be efficiently carried out across a range of institutions and sites as needed to address outbreaks of disease and other emergencies. In this RFI on Data Collection for Emergency Clinical Trials and Interoperability Pilot, issued in partnership with the Office of the National Coordinator for Health Information Technology (ONC), OSTP and ONC seek input on viable technical strategies to distribute clinical trial protocols and capture clinical trial data using common application programming interfaces (APIs), in the pre-emergency phase as well as in emergency settings. One specific objective for this RFI is to gather information about whether there is

value in a pilot or demonstration project to operationalize data capture in the near term, for example within 6–12 months of the close of comments on this RFI.

DATES: Interested persons and organizations are invited to submit comments on or before 5:00 p.m. ET on December 27, 2022.

ADDRESSES: Interested individuals and organizations should submit comments electronically to datacollectionforclinicaltrials@ostp.eop.gov and include “Data Collection for Clinical Trials RFI” in the subject line of the email. Due to time constraints, mailed paper submissions will not be accepted, and electronic submissions received after the deadline cannot be ensured to be incorporated or taken into consideration.

Instructions

Response to this RFI is voluntary. Each responding entity (individual or organization) is requested to submit only one response. Please feel free to respond to one or as many prompts as you choose.

Please be concise with your submissions, which must not exceed 10 pages in 12-point or larger font, with a page number on each page. Responses should include the name of the person(s) or organization(s) filing the comment.

OSTP invites input from all stakeholders including members of the public, representing all backgrounds and perspectives. In particular, OSTP is interested in input from health information technology (health IT) companies, app developers, clinical trial designers, and users of health IT products. *Please indicate which of these stakeholder types, or what other description, best fits you as a respondent.* If a comment is submitted on behalf of an organization, the individual respondent's role in the organization may also be provided on a voluntary basis.

Comments containing references, studies, research, and other empirical data that are not widely published should include copies or electronic links of the referenced materials. No business proprietary information, copyrighted information, or personally identifiable information should be submitted in response to this RFI. Please be aware that comments submitted in response to this RFI may be posted on OSTP's website or otherwise released publicly.

In accordance with FAR 15.202(3), responses to this notice are not offers and cannot be accepted by the Federal